# Study Evaluating Safety, Tolerability, and Efficacy of Intravenous AP-SA02 in Subjects With S. Aureus Bacteremia

> **NCT05184764** · PHASE1,PHASE2 · COMPLETED · sponsor: **Armata Pharmaceuticals, Inc.** · enrollment: 56 (actual)

## Conditions studied

- Bacteremia
- Staphylococcus Aureus
- Staphylococcus Aureus Bacteremia
- Bacteremia Staph
- Bacteremia Due to Staphylococcus Aureus

## Interventions

- **BIOLOGICAL:** AP-SA02
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT05184764
- **Lead sponsor:** Armata Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-04-26
- **Primary completion:** 2024-11-07
- **Final completion:** 2025-01-14
- **Target enrollment:** 56 (ACTUAL)
- **Last updated:** 2026-03-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05184764

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05184764, "Study Evaluating Safety, Tolerability, and Efficacy of Intravenous AP-SA02 in Subjects With S. Aureus Bacteremia". Retrieved via AI Analytics 2026-07-29 from https://api.ai-analytics.org/clinical/NCT05184764. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*